Background: Increased circulating glucocorticoids are features of both aging and Alzheimer's disease (AD), and increased glucocorticoids accelerate the accumulation of AD pathologies. Here, we analyzed the effects of the glucocorticoid receptor antagonist mifepristone (RU486) in the 3xTg-AD mouse model at an age where hippocampal damage leads to high circulating corticosterone levels.
A lzheimer's disease (AD) is the most prevalent cause of dementia in the elderly, with only palliative treatments available at this time. It has been shown that AD patients display significant elevated levels of the glucocorticoid hormone cortisol in plasma and cerebrospinal fluid, as well as hypothalamic-pituitary-adrenal (HPA) axis dysfunction (1) (2) (3) .
We previously showed that glucocorticoids (GCs) (cortisol in humans and corticosterone in rodents) could drive the formation of AD hallmark pathologies through increased production of the amyloid beta (Ab) peptide and accumulation of somatodendritic tau (4) . In addition, both stress and increased GC exposure have shown to induce cognitive impairments, trigger amyloid precursor protein (APP) misprocessing, reduce Ab clearance by decreasing activity of insulin degrading enzyme (IDE), and stimulating tau hyperphosphorylation (5-9), together demonstrating a key role for GCs in the progression of AD pathology and cognitive decline. Glucocorticoids are key stress hormones secreted by the adrenal gland and controlled by the HPA axis, which mediate their effects in the different brain areas through two types of receptors: mineralocorticoid type I receptors and glucocorticoid type II receptors (GR) (10) . Recently, the GR have been implicated in epigenetic mechanisms of neurodegeneration via histone deacetylase 2 (11) .
The current study investigates the therapeutic potential of the glucocorticoid receptor antagonist mifepristone (RU486) on both cognitive and pathological outcomes in the 3xTg-AD mouse model of AD. 3xTg-AD mice show increased circulating levels of GCs from 9 months of age, when hippocampal pathology is advanced (4) . Hence, we sought to evaluate if blocking the effects of GCs could help reduce pathology and cognitive decline in animals of this age. Here, we report that the GR blocker, mifepristone, has unparalleled effects on both outcomes, leading to robust reductions in Ab levels and plaques through the induction of a 17-kDa cleavage of APP, precluding Ab generation. In addition, it restores cyclic-AMP response element-binding protein (CREB) signaling and reduces tau hyperphosphorylation via reductions in p25 levels. Hence, our results show that compounds targeting the glucocorticoid system could be useful for the treatment of AD, in part through novel disease-modifying effects on Ab generation.
Methods and Materials Transgenic Mice and Treatment
All animal procedures were performed in accordance with National Institutes of Health and University of California guidelines and Use Committee at the University of California, Irvine. The characterization of 3xTg-AD mice has been described previously (12) . In this study, 12-month-old homozygous nontransgenic (Ntg) and 3xTg-AD mice, 8 to 10 per group (male animals) were anesthetized with isoflurane and drug pellets containing the glucocorticoid receptor antagonist mifepristone (17b-hydroxy-11a-(4-dimethylaminophenyl)-17a-(1-propynyl)-estra-4,9-dien-3-one) (Innovative Research of America, Sarasota, Florida) or vehicle pellets were implanted subcutaneous according to the manufacturer's instructions. In addition, 10-month-old homozygous 3xTg-AD mice, 10 per group (male animals) were anesthetized with isoflurane and drug pellets containing the selective glucocorticoid antagonist Cort-108297 ((R)-4a-Ethoxymethyl-1-(4-fluorophenyl)-6-(4-trifluoromethyl-benzenesulfonyl0-4,4a,5,6,7,8-hexahydro-1H-1,2,6-triaza-cyclopenta[b]naphthalene) (Corcept Therapeutics, Menlo Park, California) or vehicle pellets were implanted subcutaneous. The animals were treated for 21 days with 25.2 mg pellets that released a continuous flow of the drug at 1.2 mg per day (13) (14) (15) .
Behavior Testing
Novel context, place, and object were conducted as described previously (16) . Open field was performed as previously described (16) . Hidden Morris water maze (MWM) tests were conducted as described previously (17, 18) . The passive inhibitory avoidance task was performed as described previously (19, 20) .
Tissue Preparation
Tissue preparation was performed as previously described (17, 18) . For protease analyses, whole brains were homogenized with/without complete protease inhibitor cocktail tablets (Roche Diagnostics GmbH, Mannheim, Germany) or specific families of protease inhibitor (leupeptin: 10 mg/mL; E64: 10 mmol/L; aprotinin: 10 mg/mL; pepstatin: 1 mmol/L; phosphoramidon: 10 mmol/ L [Sigma-Aldrich, St. Louis, Missouri]), in the presence or absence of calcium in assay buffer (assay buffer: 135 mmol/L sodium chloride, 5 mmol/L potassium chloride, 1.2 mmol/L magnesium sulfate, 5 mmol/L N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, 10 mmol/L glucose, and 2.5 mmol/L calcium chloride). The samples were incubated 20 minutes at 371C with the differences protease inhibitors and then immunoblotted for APP fragments using C-terminal antibody CT20 (Calbiochem, San Diego, California).
Immunohistochemistry
Immunohistochemistry for light microscopy was performed as we described previously (21) . The following antibodies were used: anti-6E10 (1:1000; Covance Research Products, Denver, Pennsylvania) and PHF1 (1:1000; Pierce Biotechnology). The specificity of the immune reactions was controlled by omitting the primary antibody.
Total Ab Loading
Quantification of total Ab content was performed as previously described (21) .
Immunoblotting
Immunoblot analyses were performed as described (4) . The following primary antibodies were used: anti-CREB (1:1000; Cell Signaling), anti-phospho-CREB (ser133) (1:1000; Cell Signaling), anti-CTF20 (1:5000; Calbiochem) for C99 and C83, anti-HT7 (1:5000; Pierce Biotechnology), anti-AT8 (1:1000; Pierce Biotechnology), anti-AT180 (1:1000; Pierce Biotechnology), anti-AT270 (1:1000; Pierce Biotechnology), anti-PHF1 (Dr. Peter Davies, Albert Einstein College of Medicine, Manhasset, New York), anti-ADAM10 (1:1000; Calbiochem), anti-BACE (1:1000; Calbiochem), anti-IDE (1:1000; Chemicon), anti-total glycogen synthase kinase 3 (GSK3) a and b (1:5000; Calbiochem), anti-pGSK3b (ser9) (1:3000; Cell Signaling), anti-cyclin-dependent kinase 5 (Cdk5) (1:1000; Calbiochem), anti-C'-term p35 (1:200; Santa Cruz Biotechnology, Santa Cruz, California) for p25 and p35, anti-PP2A (1:1000; Santa Cruz Biotechnology), and anti-glyceraldehyde 3-phosphate dehydrogenase (1:5000; Santa Cruz Biotechnology).
Enzyme-Linked Immunosorbent Assay for Ab 40 and Ab 42 Ab 1-40 and Ab were measured using a sensitive sandwich enzyme-linked immunosorbent assay system as previously described (4) .
Mass Spectrometry of Mifepristone
Plasma (30 uL) was vortexed with 200 uL of dichloromethane, and the dichloromethane fraction was taken and air-dried. The precipitate was dissolved in 50 uL of 50% acetonitrile and then separated on an Acquity UltraPerformance LC (Waters Corporation, Milford, Massachusetts) and then analyzed on a Quatro Premier XE. Mifepristone standards showed fragments of molecular weight 134 and 370, which were positively identified in the plasma samples.
Quantitative and Statistical Analyses
All immunoblot data were quantitatively analyzed using ImageJ 1.4 software (Center for Information Technology National Institutes of Health, Bethesda, Maryland). Statistical evaluation of the results was performed using Student t test comparison to compare two groups or two-way analysis of variance (ANOVA). After significant analyses of variance, multiple post hoc comparisons were performed using Bonferroni's test. Analysis of MWM acquisition was evaluated via repeated measure of variance. The significance was set at 95% of confidence. All values are presented as mean Ϯ SEM. All tests were performed using Graphpad Prism software (Graphpad Prism Inc., San Diego, California).
Results

Mifepristone Rescues Cognitive Deficits in Aged 3xTg-AD Mice
Male 3xTg-AD mice (12-month-old) were implanted with subcutaneous pellets containing 15 mg mifepristone or vehicle pellets designed to release a continuous flow of 10 mg per hour for 60 days. This concentration of mifepristone has proven effective to inhibit GR activity in mice (22, 23) . To determine whether mifepristone treatment could rescue cognitive deficits, 3xTg-AD mice were tested on a battery of behavioral tasks. Testing occurred during the last 2 weeks of treatment and probed cortical, hippocampal, and amygdala-dependent memory tasks, brain areas that are most severely affected by AD-like pathology in the 3xTg-AD (12, 24) .
Treated and vehicle-treated 3xTg-AD and Ntg mice were first tested on novel context/place/object tasks. These tasks are mainly hippocampal and cortical dependent, respectively. Vehicle-treated 3xTg-AD mice were significantly impaired compared with Ntg mice only on the novel object task, spending 50.17 Ϯ 12.99% of their time exploring the out-of-context object, 47.09 Ϯ 7.56% of their time exploring the out-of-place object, and 44.53 Ϯ 9.87% of their time exploring the new object ( Figure 3xTg-AD mice were tested on another hippocampaldependent behavior task, the MWM. Vehicle-treated 3xTg-AD mice reached criterion after 7 days (escape latency Ͻ25 seconds), whereas mifepristone-treated 3xTg-AD and Ntg vehicle and mifepristone-treated mice required only 5 days ( Figure 1D ). Furthermore, mifepristone treatment improved long-term memory (24-hour probe) in the 3xTg-AD mice compared with vehicletreated mice, as determined by the significant increase in the duration of time in the platform quadrant and reduced time in the opposite quadrant ( Figure 1E ,F). These data were confirmed by the analysis of the swim patterns in the test session ( Figure 1G) . Notably, the effects of mifepristone on water maze performance were not directly related to motor alterations, since no significant variations of the swimming speed or total distance traveled in the water maze were observed in mifepristone compared with vehicle-treated mice ( Figure S1A ,B in Supplement 1).
In addition, no differences between vehicle-and mifepristonetreated mice were seen on the open field test ( Figure S1C in Supplement 1). Finally, 3xTg-AD mice were trained in a contextual learning and memory task (passive inhibitory avoidance) primarily dependent on the amygdala (25) . A 24-hour memory test revealed no differences between vehicle-and mifepristonetreated mice ( Figure S1D in Supplement 1), pointing to a lack of improvement with mifepristone treatment. We confirmed the presence of mifepristone in the plasma at the end of the experiment via mass spectrometry.
Mifepristone Regulates CREB Signaling in 3xTg-AD but not Wild-Type Mice
Deficits in CREB signaling have been associated with impaired learning in 3xTg-AD mice (26) . Western blot analyses of brain homogenates showed upregulation in steady-state levels of both CREB (41.17 Ϯ 16.15%, two-way ANOVA, Bonferroni post hoc p ¼ .07) and phospho-CREB (47.65 Ϯ 9.20%, two-way ANOVA, Bonferroni post hoc p ¼ .07) with mifepristone treatment compared with vehicle. In addition, no differences were observed in Ntg mice in CREB or phospho-CREB with either vehicle or mifepristone. Notably, significant decreases (for CREB 56.40 Ϯ 11.97%, two-way ANOVA, Bonferroni post hoc, p Ͻ .05, and for phospho-CREB 50.28 Ϯ 8.74%, two-way ANOVA, Bonferroni post hoc, p Ͻ .05) in steady-state level of CREB and phospho-CREB were observed between Ntg and 3xTg-AD mice (Figure 2A,B Figure 3B ). In agreement with the enzyme-linked immunosorbent assay data, immunostaining analysis with antibody 6E10 showed intense reduction of extracellular deposits in mifepristone-treated compared with vehicle-treated mice ( Figure 3C, 1-8) ; it should be noted that intracellular staining is likely due to a combination of Ab as well as intracellular APP. Thus, the results showed a significant decrease in the subiculum (45.18 Ϯ 10.16%, p Ͻ .05, t test) and cornu ammonis 1 hippocampal subfields (44.91 Ϯ 7.70%, p Ͻ .05, t test) and the entorhinal cortex (64.91 Ϯ 4.01%, p Ͻ .05, t test). Of significance to the cognitive data, we did not observe any significant changes in plaque load in the amygdala ( Figure 3D ). In addition, intracellular immunolabeling expression patterns were similar in mifepristone-and vehicletreated mice in all analyzed brain areas ( Figure 3C ).
Mifepristone Induces a Novel 17-kDa APP Fragment that Precludes Ab Generation
Steady-state levels of full-length APP holoprotein were unaffected by mifepristone treatment, as expected, as APP (and tau) were under the control of the thy1.2 transgene promoter in the 3xTg-AD mice. Using a C-terminal APP antibody [CT20 (27) ], significant reductions in steady-state levels of both C83 (33.45 Ϯ 7.49%, p Ͻ .01, t test) and C99 (36.88 Ϯ 6.86%, p Ͻ .05, t test) were observed with mifepristone treatment ( Figure 4A-C) . Both C-terminal fragments (CTFs) were reduced by the same degree, which is unusual, as these fragments are usually mutually exclusive and also given no reductions in the parent holoprotein APP. Instead, we observed the appearance of a 17-kDa APP fragment only in mifepristone-treated animals; the 17-kDa fragment represented the last C' 17-kDa of APP, which contained both the C99 and C83 sequence. As such, we deduced that this novel fragment was produced with mifepristone treatment and neither C99 nor C83 were produced, thus bypassing Ab generation and explaining the concomitant reductions in both C99 and C83. We repeated this experiment using a different Cterminal antibody lot ( Figure 4B ), as a nonspecific band at 18-kDa was observed with the initial lot ( Figure 4A ). In confirmation of this pathway in the 3xTg-AD mice, we analyzed steady-state levels of endogenous APP and APP C-terminal fragments in Ntg mice treated with mifepristone. We found no changes in full length APP with mifepristone treatment but trended to reductions in the APP CTFs (27.32 Ϯ 12.07%, p ¼ .08, t test) compared with vehicle Ntg mice ( Figure S2A ,B in Supplement 1).
We analyzed steady-state levels of the constitutive protease asecretase (ADAM10), b-secretase (BACE1) (28) (29) (30) (31) , and IDE (32), and found no differences with treatment ( Figure 4D,E) .
We reasoned that the protease responsible for the generation of the 17-kDa APP fragment was probably present in the brain but was unable to interact with APP under normal conditions. To test this, we took fresh brains from 3xTg-AD mice and homogenized them with our usual T-Per detergent buffer (Thermo Scientific, Rockford, Illinois) or a mild assay buffer with and without protease inhibitors. We found that brains homogenized in assay buffer in the absence of protease inhibitors generated the 17-kDa APP fragment ( Figure 4F,H) , but its production was blocked by the presence of protease inhibitors or by T-Per buffer. We then set to characterize the responsible APP protease further by incubating 3xTg-AD whole-brain homogenates in assay buffer for 20 minutes with specific proteases inhibitors. Brains incubated with leupeptin (serine and cysteine protease inhibitor) and E64 (cysteine protease inhibitor) blocked the formation of the 17-kDa C-terminal fragment. However, 3xTg-AD brain incubated with aprotinin (serine protease inhibitor), pepstatin (aspartyl protease inhibitor), and phosphoramidon (metalloendopeptidase inhibitor) was not able to block the formation of 17-kDa C-terminal fragment ( Figure 4G,I ). These data indicate that a cysteine protease is involved in the formation of the 17-kDa C-terminal fragment in the 3xTg-AD mice. In addition, when brain samples were incubated in assay buffer without calcium and with ethylene glycol tetraacetic acid, the generation of the 17-kDa C-terminal fragment was blocked ( Figure 4G, I ). These data indicate that a calcium-dependent cysteine protease generates the 17-kDa C-terminal fragment in 3xTg-AD mice.
Mifepristone Reduces Accumulation of Tau Phosphorylated at Epitopes Thr181 and Ser396/404
Previous studies showed that glucocorticoids stimulate tau hyperphosphorylation and alter tau trafficking and stability (9, 33) . Subsequently, we examined the effects of mifepristone on tau phosphorylation. Western blot analyses of soluble brain homogenates revealed reductions in tau levels phosphorylated at residues Thr181 (46.89 Ϯ 13.91%, p Ͻ .05, t test, and recognized by the AT270 antibody) and Ser396/404 (35.32 Ϯ 13.69%, p Ͻ .05, t test, and recognized by the PHF1 antibody). Levels of phospho-tau species recognized by antibodies AT8 (Ser199/202) and AT180 (Thr231) were unaffected by mifepristone treatment versus vehicle treatment ( Figure 5A,B) . In correlation with biochemical analysis, immunohistochemistry of hippocampal sections (cornu ammonis 1 and subiculum) showed marked reductions in somatodendritic phospho-tau accumulation and aggregation in the pyramidal cell layer in the 3xTg-AD mifepristone-treated mice compared with vehicle ( Figure 5C1-C4,C5 ). In addition, reductions in the number of dystrophic neurites positive for PHF1 were observed in the subiculum area of animals treated with mifepristone versus vehicle ( Figure 5C6) .
Finally, to elucidate the cellular mechanisms through which mifepristone reduces tau phosphorylation in the 3xTg-AD, we examined total and activated forms of Cdk5 and GSK3-b, two major kinases associated with abnormal tau phosphorylation in the brain (34) (35) (36) (37) . The results showed significant reductions in the steady-state levels of Cdk5 (32.66 Ϯ 6.67%, p Ͻ .05, t test) and the cytosolic activator of Cdk5, p25 (35.32 Ϯ 13.69%, p Ͻ .05, t test) in the mifepristone-treated mice ( Figure 6D,E) . Notably, we observed significant increases in steady-state levels of p35 (250.78 Ϯ 8.34%, p Ͻ .001, t test) ( Figure 5D,E) . Similar results were observed in the steady-state levels of p25 in Ntg mice treated with mifepristone (46.64 Ϯ 2.82%, p Ͻ .01, t test) ( Figure S2C ,D in Supplement 1) ; the cysteine protease calpain (38) , suggesting that mifepristone could inhibit calpain activity. Steady-state levels of GSK3-b, pS9-GSK3-b (inactive GSK3-b phosphorylated at ser9), extracellular signal-regulated kinase, phosphorylated extracellular signal-regulated kinase, c-Jun N-terminal kinase, phosphoc-Jun N-terminal kinase, and PP2A (tau phosphatase), were unaffected by mifepristone treatment (Figure 5D,E) . In correlation with the cognitive data, immunostaining analysis of the amygdala showed no differences in the expression of total human tau, while similar low numbers of PHF1 positive cells were observed in both 3xTg-AD vehicle-and mifepristonetreated mice ( Figure S3A ,B in Supplement 1). Our results indicate that mifepristone mediates reduction of phospho-tau levels on residues Thr181 and Ser396/404 correlating with inactivation of Cdk5/p25 in the 3xTg-AD.
A Specific GR Antagonist Reduces APP CTFs and p25
Mifepristone is an antagonist at both the GR and progesterone receptor (PR). To explore which of these targets were mediating the effects seen in the 3xTg-AD mice, we obtained the specific GR antagonist Cort-108297 (13-15) (a generous gift from Corcept Therapeutics). We manufactured slow-release pellets and implanted them, or placebo pellets, subcutaneous for 21 days. At the end of this period, we analyzed brain homogenates for APP fragments, Ab and p25 levels ( Figure 6A-F) . Consistent with mifepristone treatment, Cort-108297 significantly reduced levels of C83 (35.32 Ϯ 8.02%, p Ͻ .05, t test) and trended toward a decrease in C99. Likewise, levels of p25 (48.02 Ϯ 34.19%, p Ͻ .05, t test) were significantly reduced with treatment. However, levels of Ab were not significantly reduced, but this could be related to the shorter treatment duration than the experiments performed with mifepristone.
Discussion
There is ample evidence implicating HPA axis dysfunction in AD, reflected by markedly elevated basal levels of circulating cortisol and a failure to show cortisol suppression following a dexamethasone challenge (1-3) . We previously demonstrated that elevated circulating glucocorticoids could rapidly increase levels of both Ab and tau protein in the brains of transgenic mice (4), whereas others showed similar results through changes in Ab ; E64, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)-butane; L, leupeptin; MW, molecular weight; NPI, nonprotease inhibitors; P, pepstatin; PI, protease inhibitors; P-R, phosphoramidon. degradation and increases in tau phosphorylation, suggesting that these elevated cortisol levels in AD could drive some of the pathological progression (5-9). Recently, the corticotropinreleasing factor receptor has also been implicated in the progression of tau pathology, highlighting a link between stress and AD (39) . In addition, it is known that prolonged exposure and high levels of GCs is associated with neuronal damage and cognitive decline in the central nervous system (CNS) (40) (41) (42) . Thus, we investigated if antiglucocorticoid strategies could offer a viable therapeutic approach.
This study shows clear cognitive improvements in a number of domains with treatment of aged 3xTg-AD mice with the glucocorticoid and progesterone receptor blocker mifepristone. Although these improvements are likely due to the marked reductions in both Ab and tau pathologies in mifepristone-treated mice, antiglucocorticoid drugs, through 11-b hydroxysteroid dehydrogenase inhibitors, have recently been shown to improve cognition in aged mice of their own (43, 44) . Of note, a small clinical trial in AD patients treated with mifepristone for just 6 weeks reported an increase in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (45) , although this short time frame is unlikely to have reversed pathology in humans.
Although glucocorticoid-reducing compounds may exhibit cognitive-enhancing capabilities on their own, treatment with mifepristone led to profound reductions in both soluble and insoluble Ab levels in the 3xTg-AD mice. These reductions in Ab appear to be due to the induction of a novel APP processing pathway in which APP is cleaved 17-kDa from the C-terminal, by an unidentified protease, rather than by either asecretase or b-secretase. As such, C99 (and C83) formation is prevented, and by extension, so is Ab formation. We recently described this novel APP processing pathway in the CNS of AD transgenic mice and cynomolgus primates using a small molecular compound known as ST101, with no known molecular (46) . Here, we show that mifepristone stimulates the same novel APP processing pathway and leads to larger reductions in AD-related pathology, as well as robust improvements in cognition. We hypothesize that mifepristone is either modulating the activity of this unknown APP protease or that it is altering the subcellular location of either APP or the protease such that they can interact in the presence of mifepristone. To this end, we show that the untreated brain has the ability to make this 17-kDa APP fragment in the absence of protease inhibitors, showing that the protease is always present but does not normally cleave APP. Furthermore, we find that only inhibitors of cysteine proteases can block the formation of this APP fragment, and that calcium is necessary. Thus, an APP calcium-dependent cysteine protease exists but its identity is unknown. Prominent calcium-dependent cysteine proteases include the calpains-here, we find that mifepristone downregulates p25 levels, which themselves are a product of calpain activity. Thus, it is unlikely that calpains are the unidentified APP protease, and further experiments will be required to fully identify it. Mifepristone also attenuated tau pathology in the 3xTg-AD mice, through reduction of steady-state levels of phospho-tau on residues Thr181 and Ser396/404, concomitant with reductions in p25 in both Ntg and 3xTg-AD mice. We also observed significant reductions in the number of cell and dystrophic neurites positive for PHF1 in 3xTg-AD treated with mifepristone versus vehicle. In agreement with this, previous studies have shown that elevated GCs can increase tau phosphorylation (9, 33) .
In addition, the PR has been implicated in both cognitive improvements (47, 48) and reductions in pathology (49, 50) in mouse models of AD. For example, the progesterone metabolite allopregnanolone improves cognition in the 3xTg-AD mice via increases in neurogenesis (51, 52) and reduces Ab accumulation (53) , and progesterone itself improves cognition in APP mice (49) and also reduces tau hyperphosphorylation in 3xTg-AD mice (50) . Notably, mifepristone can be metabolized in both the periphery and CNS (54) , and these newly formed metabolites can bind to both the GR and PR (55) . Furthermore, treatment with a specific GR antagonist, Cort-108297, was able to reduce APP CTFs and p25, thus mimicking some of the effects of mifepristone. These results suggest that the effect observed by mifepristone is related by modulation of GC instead of PR receptor. However, we cannot discard that PR or other steroid receptor could be modulated by mifepristone. Future research using knockout mice for GR, PR, or other steroid hormone will be necessary to elucidate the effect of mifepristone to these receptors.
Cyclic-AMP response element-binding protein signaling is impaired in 3xTg-AD mice, and restoration of CREB signaling restores cognitive function (26) . Hence, we next looked at levels of CREB and phospho-CREB and found both to be significantly increased in mifepristone-treated mice versus vehicle. Notably, no effects were seen in Ntg mice. These results suggest that 1) the effects on CREB signaling are mediated by the reductions in pathology rather than a direct effect of mifepristone, as the wild-type mice were not affected; and 2) increases in CREB signaling could be mediating the improved cognition in the 3xTg-AD mice.
Hence, mifepristone and other GR targeting strategies may offer potential benefit for the treatment of AD.
